NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis → The 7th Trillion Dollar Company? (From The Oxford Club) (Ad) Free CMPX Stock Alerts $1.53 +0.06 (+4.08%) (As of 03:38 PM ET) Add Compare Share Share Today's Range$1.47▼$1.5750-Day Range$1.44▼$2.2452-Week Range$1.15▼$3.45Volume91,312 shsAverage Volume420,646 shsMarket Capitalization$210.51 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Compass Therapeutics alerts: Email Address Compass Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside488.2% Upside$9.00 Price TargetShort InterestBearish1.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.25Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.41) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector507th out of 931 stocksBiological Products, Except Diagnostic Industry79th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Compass Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.85% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPX. Previous Next 3.5 News and Social Media Coverage News SentimentCompass Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Compass Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows1 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.41) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Compass Therapeutics Stock (NASDAQ:CMPX)Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Read More CMPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPX Stock News HeadlinesMay 23, 2024 | globenewswire.comCompass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 14, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical TrialsMay 14, 2024 | globenewswire.comCompass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 13, 2024 | investorplace.comCMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024May 13, 2024 | globenewswire.comCompass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate UpdateApril 25, 2024 | finance.yahoo.comCompass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedApril 17, 2024 | benzinga.comCompass Therapeutics Stock (NASDAQ:CMPX), Analyst Ratings, Price Targets, PredictionsApril 12, 2024 | globenewswire.comCompass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual ConferenceApril 11, 2024 | investing.comCompass Therapeutics reports potential in tumor treatmentApril 10, 2024 | finance.yahoo.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 10, 2024 | globenewswire.comCompass Therapeutics to Participate in the Stifel Targeted Oncology DaysApril 9, 2024 | globenewswire.comCompass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2024 | markets.businessinsider.comCompass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic MilestonesMarch 24, 2024 | investorplace.com3 Penny Stocks With the Power to 10X Your $1K InvestmentMarch 22, 2024 | markets.businessinsider.comCompass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy RatingMarch 21, 2024 | globenewswire.comCompass Therapeutics Reports 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | finance.yahoo.comWith 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional ownersFebruary 29, 2024 | globenewswire.comCompass Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | finance.yahoo.comCompass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical TrialFebruary 8, 2024 | msn.comCompass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should KnowFebruary 2, 2024 | morningstar.comCompass Therapeutics Inc Ordinary SharesJanuary 31, 2024 | finance.yahoo.comWe're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn RateJanuary 5, 2024 | finance.yahoo.comCompass Therapeutics Provides Corporate UpdateDecember 20, 2023 | finance.yahoo.comCompass Therapeutics Insider Ups Holding During YearSee More Headlines Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/28/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CMPX CUSIPN/A CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+492.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.67% Return on Assets-27.24% Debt Debt-to-Equity RatioN/A Current Ratio40.74 Quick Ratio40.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.30Miscellaneous Outstanding Shares137,590,000Free Float96,312,000Market Cap$209.14 million OptionableNot Optionable Beta0.92 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Vered Bisker-Leib M.D. (Age 53)MBA, Ph.D., CEO & Director Comp: $719kDr. Thomas J. Schuetz M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Vice Chairman of the Board Comp: $835.88kMr. Neil L. Lerner CPA (Age 57)Vice President of Finance Mr. Jonathan Anderman J.D.VP, Head of Legal & Corporate SecretaryAnna GiffordCommunications ManagerDr. Minori Rosales M.D. (Age 61)Ph.D., Senior VP & Head of Clinical Development Ms. Karin Herrera B.A.VP & Head of Clinical OperationsDr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & ControlsMore ExecutivesKey CompetitorsPCB BancorpNASDAQ:PCBMonte Rosa TherapeuticsNASDAQ:GLUEAcumen PharmaceuticalsNASDAQ:ABOSINmune BioNASDAQ:INMBAgenusNASDAQ:AGENView All CompetitorsInstitutional OwnershipJanus Henderson Group PLCSold 54,331 shares on 5/16/2024Ownership: 4.719%CM Management LLCBought 185,000 shares on 5/14/2024Ownership: 0.225%Vanguard Group Inc.Bought 71,008 shares on 5/10/2024Ownership: 3.018%Bleakley Financial Group LLCBought 40,243 shares on 5/8/2024Ownership: 0.029%SG Americas Securities LLCSold 18,883 shares on 5/7/2024Ownership: 0.021%View All Institutional Transactions CMPX Stock Analysis - Frequently Asked Questions Should I buy or sell Compass Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPX shares. View CMPX analyst ratings or view top-rated stocks. What is Compass Therapeutics' stock price target for 2024? 2 analysts have issued twelve-month price objectives for Compass Therapeutics' shares. Their CMPX share price targets range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 488.2% from the stock's current price. View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts. How have CMPX shares performed in 2024? Compass Therapeutics' stock was trading at $1.56 on January 1st, 2024. Since then, CMPX shares have decreased by 1.9% and is now trading at $1.53. View the best growth stocks for 2024 here. When is Compass Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CMPX earnings forecast. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its earnings results on Thursday, March, 21st. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.02. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Compass Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.72%), Vanguard Group Inc. (3.02%), CM Management LLC (0.23%), Simplicity Wealth LLC (0.03%), Bleakley Financial Group LLC (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMPX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarElon to Transform U.S. Economy? Porter & Company[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
